Literature DB >> 10872534

Non-dipping circadian blood pressure and renal impairment are associated with increased mortality in diabetes mellitus.

N D Sturrock1, E George, N Pound, J Stevenson, G M Peck, H Sowter.   

Abstract

AIMS: To assess the relevance of circadian blood pressure variation to future morbidity and mortality in patients with diabetes mellitus.
METHODS: A retrospective descriptive 4 year follow-up study of data collected after ambulatory blood pressure monitoring in a clinic setting.
RESULTS: Seventy-five patients (46 male; 29 female) of whom 41 % had Type 1 diabetes and 59% Type 2 were followed up for a median of 42 months (11-56). The median creatinine for the whole group at baseline was 101 (56-501) micromol/l. The median circadian blood pressures for the total study population were 147 (110-194)/87 (66-109) mmHg during daytime and 132 (86-190)/77 (50-122) mmHg during night-time. Half of the patients exhibited a fall in night-time pressures to 10% lower than daytime pressures (dippers). Dippers were younger, 47 (32-75) years, than non-dippers, 57 (35-79) years, P = 0.03. Over time, dippers had a lower mortality than non-dippers, with 8% deaths in the cohort of dippers, 26% deaths in the cohort of non-dippers, P = 0.04. Cox regression analysis revealed significant contributions from age, duration of diabetes and baseline renal function to subsequent mortality in non-dippers. Analysing current degree of renal impairment and original dipper status together revealed that, of those patients whose creatinine remained normal, 7% of patients whose blood pressure dipped had subsequently died and 10% of non-dipping patients had died; of those patients whose creatinine unequivocally rose, 10% of dipping patients had died and 42% of non-dipping patients had died, P = 0.03
CONCLUSIONS: Loss of circadian variation in blood pressure is associated with an increased mortality rate, regardless of diabetes type. The combination of non-dipping and subsequent renal impairment leads to the highest mortality rate. The study suggests a role for ambulatory blood pressure monitoring in day-to-day clinical practice to select patients with nephropathy who are at greatest risk, in an effort to alter outcome.

Entities:  

Mesh:

Year:  2000        PMID: 10872534     DOI: 10.1046/j.1464-5491.2000.00284.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  48 in total

1.  The Association of Pediatric Obesity With Nocturnal Non-Dipping on 24-Hour Ambulatory Blood Pressure Monitoring.

Authors:  Ian R Macumber; Noel S Weiss; Susan M Halbach; Coral D Hanevold; Joseph T Flynn
Journal:  Am J Hypertens       Date:  2015-08-26       Impact factor: 2.689

2.  Utility and feasibility of a new programmable home blood pressure monitoring device for the assessment of nighttime blood pressure.

Authors:  Hisako Ushio; Tomoaki Ishigami; Naomi Araki; Shintaro Minegishi; Koichi Tamura; Yasuko Okano; Kazuaki Uchino; Osamu Tochikubo; Satoshi Umemura
Journal:  Clin Exp Nephrol       Date:  2009-05-19       Impact factor: 2.801

Review 3.  Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA.

Authors:  Dorrin Zarrin Khat; Mansoor Husain
Journal:  Curr Diab Rep       Date:  2018-06-09       Impact factor: 4.810

Review 4.  Chronotherapy improves blood pressure control and reduces vascular risk in CKD.

Authors:  Ramón C Hermida; Diana E Ayala; Michael H Smolensky; Artemio Mojón; José R Fernández; Juan J Crespo; Ana Moyá; María T Ríos; Francesco Portaluppi
Journal:  Nat Rev Nephrol       Date:  2013-04-23       Impact factor: 28.314

5.  Autonomic dysregulation in ob/ob mice is improved by inhibition of angiotensin-converting enzyme.

Authors:  Aline M Hilzendeger; Andrey C da Costa Goncalves; Ralph Plehm; André Diedrich; Volkmar Gross; Joao B Pesquero; Michael Bader
Journal:  J Mol Med (Berl)       Date:  2009-12-12       Impact factor: 4.599

6.  Nocturnal blood pressure fall as predictor of diabetic nephropathy in hypertensive patients with type 2 diabetes.

Authors:  João S Felício; Ana Carolina C B de Souza; Nárcia Kohlmann; Oswaldo Kohlmann; Arthur B Ribeiro; Maria T Zanella
Journal:  Cardiovasc Diabetol       Date:  2010-08-13       Impact factor: 9.951

7.  The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.

Authors:  Mai Yanagi; Kouichi Tamura; Tetsuya Fujikawa; Hiromichi Wakui; Tomohiko Kanaoka; Masato Ohsawa; Kengo Azushima; Akinobu Maeda; Hiroyuki Kobori; Satoshi Umemura
Journal:  Hypertens Res       Date:  2012-11-15       Impact factor: 3.872

8.  Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with/without type 2 diabetes.

Authors:  Kazuo Eguchi; Thomas G Pickering; Satoshi Hoshide; Joji Ishikawa; Shizukiyo Ishikawa; Joseph E Schwartz; Kazuyuki Shimada; Kazuomi Kario
Journal:  Am J Hypertens       Date:  2008-02-21       Impact factor: 2.689

Review 9.  Autonomic Dysfunction: How to Identify and When to Treat?

Authors:  Francesca Saladini; Attilio Di Marco; Paolo Palatini
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-06-24

Review 10.  Should 24-h ambulatory blood pressure monitoring be done in every patient with diabetes?

Authors:  Gianfranco Parati; Grzegorz Bilo
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.